MediPoint: Drug-Eluting Balloons - Global Analysis and Market Forecasts

Summary

GlobalData has released its medical devices report, “MediPoint: Drug-Eluting Balloons - Global Analysis and Market Forecasts”. The report is an essential source of information and analysis on the global drug-eluting balloons (DEB) market. The report provides in-depth insight into the use of DEB for coronary and peripheral applications in the lower extremity including in-stent restenosis, bifurcation lesions, small vessel disease, femoropopliteal artery and below-the-knee lesions, chronic total occlusions, acute myocardial infarction and lesions in diabetics.


The DEB market in the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India was assessed to identify and determine whether the current unmet needs are addressed, understand the challenges of DEB angioplasty and evaluate the current and future adoption of DEB for select coronary and peripheral indications.

Clients can use this report to better understand The scope of this technology and for strategic planning to explore opportunities in this dynamic market. The report also provides insights into the competitive landscape, the marketed and pipeline DEB products, the current and emerging players and comparative market analysis of different types of interventional techniques used to treat coronary and peripheral artery disease. It quantifies the unmet need in the global DEB market as well as in the individual markets of the US, the five major countries in the European Union, Japan, Brazil, China and India, highlighting the opportunity for future players. This report is built using data and information sourced from secondary sources and primary research interviews and survey with leading Interventional Cardiologists and Interventional Radiologists, with in-house analysis conducted by GlobalData’s team of industry experts.

Highlights

Key Questions Answered

- What is the current perception and adoption of DEB for treating select coronary and peripheral indications, such as ISR, small vessel disease, bifurcations and peripheral arteries in the lower extremity?
- Bare metal and drug-eluting stents have been on the market for many years; however, unmet needs still exist with respect to patency, restenosis and the need for prolonged dual anti-platelet therapy. (Q).How will DEB fulfill the unmet needs of the vascular stent market for treating coronary and peripheral artery disease?
- What is the current and future adoption of DEB in the major markets? (Q).How will adoption of DEB affect the adoption of stents such as drug-eluting, bare metal and bioabsorbable stents?
- What are the challenges and complications of DEB angioplasty that have hindered widespread adoption?
- Currently, the majority of marketed DEB use the antiproliferative drug Paclitaxel. (Q).As the next-generation of DEB with limus-based antiproliferative drugs and innovative coating technologies receive approval, how will new entrants impact the DEB market for coronary and peripheral applications?
- (Q).What are the key factors and opportunities that will drive the DEB market in terms of future adoption rates leading to a mature market?

Scope

- An overview of coronary artery disease and peripheral artery disease in the lower extremity, which includes epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines and modalities
- Annualized total drug-eluting balloon market revenue by type of disease, annual cost of disease and drug-eluting balloons adoption pattern and procedure data from 2010-2012 and forecast to 2019
- Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement and regulatory considerations, evaluating market access in each of the regions covered in the report, and implications of the drug-eluting balloon market
- Pipeline analysis: comprehensive data split across different stages of development, emerging trends and DEB designs in development, including investigation of DEB coating technology, antiproliferative agent used, balloon and catheter design and durability
- Analysis of the current and future market competition in the global drug-eluting balloon market. Insightful review of the key industry drivers, opportunities, restraints and challenges Each trend is independently researched to provide qualitative analysis of its implications

Reasons to buy

- “What Do Physicians Think” quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.

Table Of Contents

Table of Contents

1 Table of Contents 9
1.1 List of Tables 18
1.2 List of Figures 25
2 Introduction 29
2.1 Catalyst 30
2.2 Related Reports 31
3 Disease Overview 32
3.1 Overview 32
3.1.1 Coronary Artery Disease 32
3.1.2 Peripheral Artery Disease 32
3.2 Anatomy and Physiology 33
3.2.1 Coronary Arteries 33
3.2.2 Peripheral Arteries of the Lower Extremity 34
3.3 Pathophysiology 36
3.3.1 Coronary Artery Disease 36
3.3.2 Peripheral Artery Disease 37
3.4 Clinical Presentation 38
3.4.1 Symptoms 38
3.4.2 Risk Factors 41
3.4.3 Disease Classification 42
3.4.4 Diagnosis 43
3.4.5 Clinical Outcomes 46
3.5 Epidemiology 79
3.5.1 Coronary Artery Disease 79
3.5.2 Peripheral Artery Disease 84
3.6 Economic Impact of Coronary and Peripheral Artery Disease 90
3.6.1 Cost of Coronary Artery Disease 90
3.6.2 Cost of Peripheral Artery Disease 94
3.6.3 Treatment Costs of Coronary and Peripheral Artery Disease 96
4 Competitive Assessment 99
4.1 Overview 99
4.2 Product Profiles by Company 101
4.2.1 Aachen Resonance 102
4.2.2 B. Braun 104
4.2.3 Biotronik 111
4.2.4 Blue Medical 114
4.2.5 Cardionovum 120
4.2.6 C.R. Bard 126
4.2.7 Concept Medical Research 132
4.2.8 Cook Medical 136
4.2.9 Eurocor 138
4.2.10 Medrad (Bayer Healthcare) 153
4.2.11 Medtronic 155
4.2.12 Minvasys 163
5 Unmet Needs 166
5.1 Need for Better Clinical Outcomes in Specific Lesions 166
5.1.1 Chronic Total Occlusions 166
5.1.2 Small-Vessel Coronary Lesions 167
5.1.3 Long Lesions 167
5.1.4 Heavily-Calcified and Uncrossable/Undilatable Lesions 168
5.1.5 Bifurcation Lesions 168
5.2 Need for Better Revascularization of the Femoropopliteal Artery 169
5.3 Difficulty in Treating the Infrapopliteal Artery 171
5.4 Eliminating Mechanisms of Failure with Balloon Angioplasty 172
5.5 Addressing Challenges of Stenting 174
5.5.1 Risk of Post-Procedural Complications 174
5.5.2 In-Stent Restenosis 176
5.5.3 Stent-In-Stent Procedures 177
5.5.4 Prolonged Dual Antiplatelet Therapy 178
5.5.5 Lack of Homogenous Drug Distribution 179
5.5.6 Delayed Healing 179
5.5.7 Stent Fracture 180
5.5.8 Negative Vessel Remodeling 181
5.5.9 Long-Term Vessel Patency 182
5.6 Need for Effective Therapy for Specific Patient Populations 182
5.7 Lack of Clinical Data 183
5.8 Addressing the Complications of Bypass Surgery 183
5.9 Need to Improve Medical Therapy 184
5.10 Comparative Studies on Exercise Therapy for PAD 185
6 Pipeline Products 186
6.1 Overview 186
6.2 Pipeline by Stage of Development 187
6.3 Pipeline Product Profiles 189
6.3.1 NF-?B Decoy Oligo DEB 189
6.3.2 Drug-Coated AngioSculpt 191
6.3.3 BioPath 194
6.3.4 BioStream 195
6.3.5 Boston Scientific Drug-Coated Balloon 196
6.3.6 Coroflex DEBlue 197
6.3.7 Covidien Drug-Coated Balloon 199
6.3.8 Caliber Therapeutics DEB 201
6.3.9 Elixir Medical Corporation DCB 202
6.3.10 LifeTech Scientific Corporation DEB 202
6.3.11 Micell Technologies Drug-Coated Balloon 202
6.3.12 Drug-Coated Chocolate DEB 204
6.3.13 Passeo-18 Lux 206
6.3.14 Vascular Nanotransfer Technologies Drug-Coated Balloon 207
6.3.15 WOMBAT DCB 208
7 Clinical Trial Analysis 210
7.1 Overview 210
7.2 Clinical Trials to Watch 210
7.2.1 Drug-Eluting Balloons 210
7.2.2 Vascular Stents 224
8 Industry Overview 229
8.1 Procedure Trends 229
8.1.1 Factors Contributing to the Rise of Coronary and Peripheral Interventions 229
8.1.2 Coronary Artery Disease 230
8.1.3 Peripheral Artery Disease 235
8.2 Physician Decision-Making Process 243
8.3 Market Access 245
8.3.1 United States 246
8.3.2 European Union 253
8.3.3 Asia-Pacific Region 262
8.3.4 South America 271
8.4 Regulatory Issues/Recalls 275
8.4.1 Regulatory Issues 275
8.4.2 Product Recalls 276
8.5 Mergers and Acquisitions/Partnerships 276
8.5.1 Biosensors International and Eurocor 276
8.5.2 Boston Scientific Corporation and Guidant Corporation 277
8.5.3 Covidien and ev3, CV Ingenuity 277
8.5.4 C.R. Bard and Lutonix 278
8.5.5 Micell Technologies and Maxcor Lifescience 278
8.5.6 Medrad and Bayer 279
8.5.7 Medtronic and Invatec 279
9 Current and Future Players 280
9.1 Overview 280
9.2 Trends in Corporate Strategy 281
9.3 Company Profiles 284
9.3.1 Aachen Resonance 284
9.3.2 AnGes MG 285
9.3.3 AngioScore 287
9.3.4 AVIDAL Vascular 289
9.3.5 B. Braun 291
9.3.6 Biosensors International 293
9.3.7 Biotronik 295
9.3.8 Blue Medical 297
9.3.9 Boston Scientific Corporation 299
9.3.10 Caliber Therapeutics 301
9.3.11 Cardionovum 303
9.3.12 Concept Medical Research 305
9.3.13 Cook Medical 307
9.3.14 Covidien 308
9.3.15 C.R. Bard 310
9.3.16 Elixir Medical Corporation 312
9.3.17 Eurocor 314
9.3.18 LifeTech Scientific Corporation 316
9.3.19 Medtronic 318
9.3.20 Micell Technologies 320
9.3.21 Minvasys 321
9.3.22 TriReme Medical 323
9.3.23 Vascular Nanotransfer Technologies 325
10 Market Drivers, Opportunities, Barriers and Substitutes 327
10.1 Market Drivers 327
10.1.1 Rising Prevalence of Disease 328
10.1.2 Viable Treatment for Select Indications 329
10.1.3 No Metal Left Behind 334
10.1.4 Avoid Stent-in-Stent Procedures 335
10.1.5 Reduce the Need for Prolonged Dual Antiplatelet Therapy 336
10.1.6 Enhanced Vessel Healing and Better Patency 336
10.1.7 Technical Feasibility of Future Interventions 337
10.1.8 DEB as an Adjunctive Therapy 338
10.1.9 Limb Amputation 338
10.1.10 Cost Savings 339
10.1.11 Availability of Long-Term and Cost-Effective Data 340
10.1.12 Launch of DEB in the US 340
10.2 Opportunities 341
10.2.1 Improve DEB Design 341
10.2.2 DEB Hybrid Systems (DEB + Stent) 345
10.2.3 Target Indications Where Stenting is Not Satisfactory 345
10.2.4 Challenges in Treating the Femoropopliteal and Infrapopliteal Arteries 348
10.2.5 Target Challenging Patient Populations 350
10.2.6 Launch DEB in the Japanese Market 351
10.2.7 Emerging Markets 351
10.3 Market Barriers 352
10.3.1 Slow Adoption 352
10.3.2 High Selling Prices 356
10.3.3 Lack of Reimbursement 357
10.3.4 US FDA Regulatory Challenges 358
10.3.5 Healthcare Cost-Cutting and Reimbursement 359
10.3.6 Availability of Venture Capital 360
10.3.7 Medical Device Excise Tax 361
10.4 Market Substitutes 361
10.4.1 Vascular Stents 361
10.4.2 Liquid Drug Delivery Catheter 365
11 Drug-Eluting Balloon Market Analysis 368
11.1 Global Market Overview 368
11.2 Market Analysis by Type of Disease 369
11.2.1 Coronary Artery Disease 369
11.2.2 Peripheral Artery Disease in the Lower Extremity 370
11.3 Market Distribution by Indication 373
11.4 Primary Versus Adjunctive Therapy 375
11.5 Comparative Market Analysis 377
11.5.1 Coronary Artery Disease 377
11.5.2 Peripheral Artery Disease in the Lower Extremity 379
12 Country Outlooks and Forecasts 381
12.1 Overview 381
12.2 United States 383
12.2.1 Overview 383
12.2.2 Market Analysis 383
12.3 France 386
12.3.1 Overview 386
12.3.2 Market Analysis 386
12.4 Germany 389
12.4.1 Overview 389
12.4.2 Market Analysis 389
12.5 Italy 393
12.5.1 Overview 393
12.5.2 Market Analysis 393
12.6 Spain 396
12.6.1 Overview 396
12.6.2 Market Analysis 396
12.7 United Kingdom 398
12.7.1 Overview 398
12.7.2 Market Analysis 398
12.8 Japan 401
12.8.1 Overview 401
12.8.2 Market Analysis 401
12.9 Brazil 404
12.9.1 Overview 404
12.9.2 Market Analysis 404
12.10 China 406
12.10.1 Overview 406
12.10.2 Market Analysis 406
12.11 India 409
12.11.1 Overview 409
12.11.2 Market Analysis 409
13 Appendix 413
13.1 Bibliography 413
13.2 Abbreviations 445
13.3 Report Methodology 449
13.3.1 Overview 449
13.3.2 Coverage 449
13.3.3 Secondary Research 449
13.3.4 Forecasting Methodology 450
13.4 Physicians and Specialists Included in this Study 452
13.5 Physician Survey 455
13.6 About the Authors 456
13.6.1 Analysts 456
13.6.2 Global Head of Healthcare 457
13.7 About MediPoint 458
13.8 About GlobalData 458
13.9 Disclaimer 458



List of Tables

Table 1: Classification Systems for Determining the Severity of PAD Symptoms 40
Table 2: Risk Factors Associated with CAD and PAD 41
Table 3: Types of Atherosclerotic Lesions 43
Table 4: Treatment Guidelines to Improve the Symptoms of CAD* 48
Table 5: TASC II Classification of Iliac Artery Lesions 49
Table 6: TASC II Classification of Femoropopliteal Artery Lesions 50
Table 7: TASC II Classification of Infrapopliteal Artery Lesions 51
Table 8: Types of Coronary Artery Bypass Grafting 62
Table 9: Complications of Coronary/Peripheral Artery Bypass Surgery 63
Table 10: Indications for Using Drug-Eluting Balloons 67
Table 11: Drug-Eluting Balloon Coating Characteristics 69
Table 12: Drugs Incorporated Into Drug-Eluting Stents 72
Table 13: Types of Lesions Treated Using Atherectomy 75
Table 14: Global Prevalence of CAD in the Population Age ?65 Years in the Major Markets (millions), 2010-2019 80
Table 15: Global Prevalence of PAD in the Population Age ?65 Years in the Major Markets (millions), 2010-2019 85
Table 16: Direct and Indirect Healthcare Costs 90
Table 17: Healthcare Expenditures ($bn, 2008$) for CAD in the US 91
Table 18: Healthcare Expenditures ($bn) for CAD in the Five Major EU Countries, 2006 92
Table 19: Healthcare Expenditures ($bn) for PAD in the US and EU 94
Table 20: US Mean Hospital Costs* for Coronary and Peripheral Revascularization Procedures, 2010-2019 ($US) 97
Table 21: Global DEB Market ($m) for Treating Coronary and Peripheral Artery Disease, 2012 99
Table 22: Marketed DEB Products 101
Table 23: Elutax SV Product Portfolio 102
Table 24: Elutax SV SWOT Analysis, 2013 104
Table 25: SeQuent Please Product Portfolio 105
Table 26: SeQuent Please SWOT Analysis, 2013 110
Table 27: Pantera Lux Product Portfolio 111
Table 28: Pantera Lux SWOT Analysis, 2013 113
Table 29: Pioneer Product Portfolio 114
Table 30: Pioneer SWOT Analysis, 2013 116
Table 31: Protege Product Portfolio 117
Table 32: Protege SWOT Analysis, 2013 120
Table 33: Restore DEB Product Portfolio 121
Table 34: Restore DEB SWOT Analysis, 2013 122
Table 35: Legflow DEB Product Portfolio 123
Table 36: Legflow DEB SWOT Analysis, 2013 125
Table 37: Other DEB Products Developed by Cardionovum 126
Table 38: Lutonix Product Portfolio 127
Table 39: Lutonix SWOT Analysis, 2013 132
Table 40: Magic Touch Product Portfolio 133
Table 41: Magic Touch SWOT Analysis, 2013 135
Table 42: Advance 18 PTX Product Portfolio 136
Table 43: Advance 18 PTX SWOT Analysis, 2013 138
Table 44: Dior Product Portfolio 139
Table 45: Dior SWOT Analysis, 2013 145
Table 46: Freeway Family of DEB Product Portfolio 146
Table 47: Freeway Family of DEB SWOT Analysis, 2013 149
Table 48: Magical Product Portfolio 150
Table 49: Magical SWOT Analysis, 2013 152
Table 50: Cotavance Product Portfolio 153
Table 51: Cotavance SWOT Analysis, 2013 155
Table 52: IN.PACT Family DEB Product Portfolio 156
Table 53: IN.PACT SWOT Analysis, 2013 163
Table 54: Danubio Product Portfolio 164
Table 55: Danubio SWOT Analysis, 2013 165
Table 56: Global DEB Pipeline Products 188
Table 57: NF-?B Decoy Oligo DEB SWOT Analysis, 2013 191
Table 58: AngioSculpt SWOT Analysis, 2013 193
Table 59: BioPath SWOT Analysis, 2013 195
Table 60: BioStream SWOT Analysis, 2013 196
Table 61: Boston Scientific DEB SWOT Analysis, 2013 197
Table 62: Coroflex DEBlue SWOT Analysis, 2013 199
Table 63: Covidien DCB SWOT Analysis, 2013 201
Table 64: Micell Technologies’ DCB SWOT Analysis, 2013 203
Table 65: Drug-Coated Chocolate DEB SWOT Analysis, 2013 205
Table 66: Passeo-18 Lux SWOT Analysis, 2013 207
Table 67: Vascular Nanotransfer Technologies DCB SWOT Analysis, 2013 208
Table 68: WOMBAT DCB SWOT Analysis, 2013 209
Table 69: Medicare National Average of Inpatient Hospital Payment for Coronary and Peripheral Interventions, 2012-2013 252
Table 70: Reimbursement Classification of Medical Devices in Japan 269
Table 71: Aachen Resonance Company Profile 284
Table 72: Aachen Resonance, Marketed DEB Product 285
Table 73: Aachen Resonance SWOT Analysis, 2013 285
Table 74: AnGes MG Company Profile 286
Table 75: AnGes MG, Pipeline DEB Product 287
Table 76: AnGes MG SWOT Analysis, 2013 287
Table 77: AngioScore Company Profile 288
Table 78: AngioScore, Pipeline DEB Product 288
Table 79: AngioScore SWOT Analysis, 2013 289
Table 80: AVIDAL Vascular Company Profile 289
Table 81: AVIDAL Vascular, Pipeline DEB Product 290
Table 82: AVIDAL Vascular SWOT Analysis, 2013 291
Table 83: B. Braun Company Profile 291
Table 84: B. Braun, Marketed and Pipeline DEB Products 292
Table 85: B. Braun SWOT Analysis, 2013 293
Table 86: Biosensors International Company Profile 294
Table 87: Biosensors International, Pipeline DEB Products 294
Table 88: Biosensors International SWOT Analysis, 2013 295
Table 89: Biotronik Company Profile 296
Table 90: Biotronik, Marketed and Pipeline DEB Products 296
Table 91: Biotronik SWOT Analysis, 2013 297
Table 92: Blue Medical Company Profile 298
Table 93: Blue Medical, Marketed DEB Products 299
Table 94: Blue Medical SWOT Analysis, 2013 299
Table 95: Boston Scientific Corporation Company Profile 300
Table 96: Boston Scientific Corporation, Pipeline DEB Product 300
Table 97: Boston Scientific Corporation SWOT Analysis, 2013 301
Table 98: Caliber Therapeutics Company Profile 301
Table 99: Caliber Therapeutics, Pipeline DEB Product 302
Table 100: Caliber Therapeutics SWOT Analysis, 2013 302
Table 101: Cardionovum Company Profile 303
Table 102: Cardionovum, Marketed and Pipeline DEB Products 304
Table 103: Cardionovum SWOT Analysis, 2013 304
Table 104: Concept Medical Research Company Profile 305
Table 105: Concept Medical Research, Marketed DEB Product 306
Table 106: Concept Medical Research SWOT Analysis, 2013 306
Table 107: Cook Medical Company Profile 307
Table 108: Cook Medical, Marketed DEB Product 308
Table 109: Cook Medical SWOT Analysis, 2013 308
Table 110: Covidien Company Profile 309
Table 111: Covidien, Pipeline DEB Product 309
Table 112: Covidien SWOT Analysis, 2013 310
Table 113: C.R. Bard Company Profile 310
Table 114: C.R. Bard, Marketed DEB Products 311
Table 115: C.R. Bard SWOT Analysis, 2013 312
Table 116: Elixir Medical Corporation Company Profile 312
Table 117: Elixir Medical Corporation, Pipeline DEB Product 313
Table 118: Elixir Medical Corporation SWOT Analysis, 2013 313
Table 119: Eurocor Company Profile 314
Table 120: Eurocor, Marketed DEB Products 315
Table 121: Eurocor SWOT Analysis, 2013 315
Table 122: LifeTech Scientific Corporation Company Profile 316
Table 123: LifeTech Scientific, Pipeline DEB Product 317
Table 124: LifeTech Scientific SWOT Analysis, 2013 317
Table 125: Medtronic Company Profile 318
Table 126: Medtronic, Marketed DEB Products 319
Table 127: Medtronic SWOT Analysis, 2013 319
Table 128: Micell Technologies Company Profile 320
Table 129: Micell Technologies, Pipeline DEB Product 321
Table 130: Micell Technologies SWOT Analysis, 2013 321
Table 131: Minvasys Company Profile 322
Table 132: Minvasys, Marketed DEB Product 322
Table 133: Minvasys SWOT Analysis, 2013 323
Table 134: TriReme Medical Company Profile 323
Table 135: TriReme Medical, Pipeline DEB Product 324
Table 136: TriReme Medical SWOT Analysis, 2013 325
Table 137: Vascular Nanotransfer Technologies Company Profile 325
Table 138: Vascular Nanotransfer Technologies, Pipeline DEB Product 326
Table 139: Vascular Nanotransfer Technologies SWOT Analysis, 2013 326
Table 140: Global Coronary and Peripheral DEB Market ($m) Forecast, 2010-2019 369
Table 141: Global DEB Market ($m) for Treating PAD in the Lower Extremity, 2010-2019 370
Table 142: Percent of Patients with CAD or PAD Receiving Stenting with DEB Angioplasty, Global, 2012 and 2018 (N=112) 375
Table 143: DEB Sales ($m) Forecast for the United States, 2010-2019 384
Table 144: DEB Sales ($m) Forecast for France, 2010-2019 387
Table 145: DEB Sales ($m) Forecast for Germany, 2010-2019 390
Table 146: DEB Sales ($m) Forecast for Italy, 2010-2019 393
Table 147: DEB Sales ($m) Forecast for Spain, 2010-2019 397
Table 148: DEB Sales ($m) Forecast for UK, 2010-2019 399
Table 149: DEB Sales ($m) Forecast for Japan, 2010-2019 402
Table 150: DEB Sales ($m) Forecast for Brazil, 2010-2019 404
Table 151: DEB Sales ($m) Forecast for China, 2010-2019 407
Table 152: DEB Sales ($m) Forecast for India, 2010-2019 409
Table 153: Physicians Surveyed, By Country 45

1.2 List of Figures
Figure 1: Coronary Arteries of the Human Heart 33
Figure 2: Peripheral Arteries of the Lower Extremity 34
Figure 3: Pathophysiology of Coronary Artery Disease 36
Figure 4: Pathophysiology of Peripheral Artery Disease 37
Figure 5: Treatment Modalities - Coronary Artery Disease 53
Figure 6: Percent of Patients with CAD Who Receive Each Therapy Option Only, Global, 2012 and 2019 (N=58) 54
Figure 7: Treatment Modalities - Peripheral Artery Disease 55
Figure 8: Percent of Patients with PAD Who Receive Each Therapy Option Only, Global, 2012 (N=54) 56
Figure 9: Percent of Patients with PAD Who Receive Each Therapy Option Only, Global, 2012 (N=54) 57
Figure 10: Drug-Eluting Balloon 65
Figure 11: Types of Stents Used to Treat CAD and PAD 71
Figure 12: Bare Metal Stent 71
Figure 13: Drug-Eluting Stent 72
Figure 14: Covered Stents 73
Figure 15: Bioabsorbable Stent - Remedy 74
Figure 16: Types of Atherectomy 76
Figure 17: Global Prevalence of CAD in the Population Age ?65 Years in the Major Markets (millions), 2010-2019 81
Figure 18: Global Prevalence of PAD in the Population Age ?65 Years in the Major Markets (millions), 2010-2019 86
Figure 19: Healthcare Expenditures ($bn, 2008$) for CAD in the US 91
Figure 20: Healthcare Expenditures ($bn) for PAD in the US and EU 94
Figure 21: US Mean Hospital Costs* for Coronary and Peripheral Revascularization Procedures, 2010-2019 ($US) 98
Figure 22: Global DEB Market Share for Treating Peripheral Artery Disease in the Lower Extremity, 2012 100
Figure 23: Image of the Protege DEB 118
Figure 24: Percent of CAD and PAD Patients with Acute Vessel Recoil After Standard Balloon Angioplasty, Global, 2012 and 2018 (N=112) 173
Figure 25: Percent of CAD and PAD Patients with Thrombosis After Stenting, Global, 2012 and 2018 (N=112) 175
Figure 26: Percent of CAD and PAD Patients with ISR, Global, 2012 and 2018 (N=112) 176
Figure 27: Percent of CAD and PAD Patients Who Receive Stent-In-Stent Procedures, Global, 2012 and 2018 (N=112) 178
Figure 28: Percent of CAD and PAD Patients with Stent Fracture, Global, 2012 and 2018 (N=112) 181
Figure 29: Global DEB Pipeline Products by Stage of Development, 2013 187
Figure 30: AngioSculpt Scoring Balloon Expansion Profile 192
Figure 31: Drug-Coated Chocolate DEB 204
Figure 32: Population (? 65 years) of CAD Patients Receiving Interventional Procedures, US, 2010-2019 230
Figure 33: Population (? 65 years) of CAD Patients Receiving Interventional Procedures, EU*, 2010-2019 232
Figure 34: Population (? 65 years) of CAD Patients Receiving Interventional Procedures, APAC*, 2010-2019 233
Figure 35: Population (? 65 years) of CAD Patients Receiving Interventional Procedures, South America*, 2010-2019 234
Figure 36: Population (? 65 years) of PAD Patients Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, US, 2010-2019 236
Figure 37: Population (? 65 years) of PAD Patients Receiving DEB Angioplasty for the Peripheral Arteries in the Lower Extremity, US, 2010-2019 237
Figure 38: Population (? 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, EU*, 2010-2019 238
Figure 39: Population (? 65 years) with PAD Receiving DEB Angioplasty in the Peripheral Arteries in the Lower Extremity, EU*, 2010-2019 239
Figure 40: Population (? 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, APAC*, 2010-2019 240
Figure 41: Population (? 65 years) with PAD Receiving DEB Angioplasty for the Peripheral Arteries in the Lower Extremity, APAC*, 2010-2019 241
Figure 42: Population (? 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, South America*, 2010-2019 242
Figure 43: Population (? 65 years) with PAD Receiving DEB Angioplasty for the Peripheral Arteries in the Lower Extremity, South America*, 2010-2019 243
Figure 44: Medicare National Average of Outpatient Hospitalization Payment for PCI and Endovascular Procedures, 2012-2013 253
Figure 45: DEB Market for Treating CAD and PAD in the Lower Extremity, Company Share (%), 2012 280
Figure 46: DEB Market for Each Type of Disease, Company Share (%), 2012 282
Figure 47: Importance of Each Therapy Attribute in Adopting DEB for the Treatment of CAD and PAD, Global, 2012 (N=112) 342
Figure 48: Global DEB Market ($m) for Treating Coronary Artery Disease and Peripheral Artery Disease in the Lower Extremity, 2010-2019 368
Figure 49: Global DEB Market ($m) for Treating PAD in the Lower Extremity, 2010-2019 371
Figure 50: Global DEB Market Share for Peripheral Artery Revascularization in the Lower Extremity , 2012 and 2019 372
Figure 51: Global DEB Market Distribution (%) by Indication, 2012 and 2018 (N=112) 374
Figure 52: Percent of Patients with CAD Receiving Each Type of Interventional Technique Only, Global, 2018 (N=58) 378
Figure 53: Percent of Patients with Lower Limb PAD Receiving Each Type of Interventional Technique Only, Global, 2018 (N=54) 379
Figure 54: Global DEB Market Revenue ($m), 2012 and 2019 382
Figure 55: US DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 384
Figure 56: French DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 388
Figure 57: German DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 390
Figure 58: Italian DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 394
Figure 59: Spanish DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 397
Figure 60: UK DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 400
Figure 61: Japanese DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 402
Figure 62: Brazilian DEB Balloons Market ($m) for Coronary and Peripheral Applications, 2010-2019 405
Figure 63: Chinese DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 407
Figure 64: Indian DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 410



Companies Mentioned

Aachen Resonance
AnGes MG
AngioScore
AVIDAL Vascular
B. Braun
Biosensors International
Biotronik
Blue Medical
Boston Scientific Corporation
Caliber Therapeutics
Cardionovum
Concept Medical Research
Cook Medical
Covidien
C.R. Bard
Elixir Medical Corporation
Eurocor
LifeTech Scientific Corporation
Medtronic
Micell Technologies
Minvasys
TriReme Medical
Vascular Nanotransfer Technologies

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • July 2014
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded ...

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

1 Companies

Company Profiles

Pfizer Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.